JBC Ideal method for primary cell transfection

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M308166200 on August 25, 2003

J. Biol. Chem., Vol. 278, Issue 44, 43067-43073, October 31, 2003
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
278/44/43067    most recent
M308166200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zakharova, N.
Right arrow Articles by Darnell, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zakharova, N.
Right arrow Articles by Darnell, J. E., Jr.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Distinct Transcriptional Activation Functions of STAT1{alpha} and STAT1{beta} on DNA and Chromatin Templates*

Natalia Zakharova{ddagger}§, Elena S. Lymar§, Edward Yang{ddagger}, Sohail Malik¶, J. Jillian Zhang||, Robert G. Roeder¶, and James E. Darnell, Jr.{ddagger}**

From the Laboratories of {ddagger}Molecular Cell Biology and Biochemistry and Molecular Biology, Rockefeller University, New York, New York 10021 and ||Department of Pathology, Weill Medical College of Cornell University, New York, New York 10021

Received for publication, July 25, 2003 , and in revised form, August 22, 2003.


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Interferon-induced transcription depends upon tyrosine phosphorylation, subsequent dimerization, and binding to DNA of STAT1. Other factors, including but not necessarily limited to CBP/p300, then bind within the C-terminal 38 amino acid transactivation domain (TAD) to activate transcription. We show that both tyrosine-phosphorylated STAT1{alpha} (full-length wild-type protein) and STAT1{beta} (lacking the TAD) stimulate in vitro transcription on a naked DNA template. Furthermore, in a system with purified proteins and naked DNA, STAT1{alpha}- and STAT1{beta}-dependent transcription is stimulated by the TRAP/Mediator co-activator complex. Thus STAT1, through some site other than the C-terminal TAD, can interact with TRAP/Mediator or some intermediate protein. Although both STAT1{alpha} and STAT1{beta} bind to known STAT sites within in vitro assembled chromatin templates, only STAT1{alpha}, and not STAT1{beta}, in cooperation with p300 and acetyl-CoA, stimulated in vitro transcription from chromatin. After interferon-{gamma} treatment, cells recruit STAT1{alpha} or -{beta} to the chromosomal interferon-1 gene, but only STAT1{alpha}-containing cells recruit p300 and stimulate transcription. We conclude that chromatin remodeling by p300 in vivo makes TRAP/Mediator effective in stimulating transcription.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The signal transducers and activators of transcription (STAT)1 proteins were discovered as interferon (IFN)-induced DNA-binding proteins that bound to sequences upstream of IFN-induced genes (13). These binding sites are capable of directing IFN-induced transcription of synthetic reporter genes in transfection experiments. Extensive studies of this family of transcription factors by mutagenesis and by reintroduction of mutant proteins into cells lacking particular STATs has allowed assignment of various functions to physical domains of the STATs that were then specifically delineated by crystallography (35). Thus, residues from ~320 to 485 form the DNA binding domain. Residues from 580 to 680 form an SH2 domain, which, by reciprocal SH2-pY interactions, provides the only protein contact in DNA-bound dimers. Residues from 1 to 130 form an N-terminal domain that allows a STAT dimer-dimer interaction on DNA (68), which greatly strengthens DNA binding and increases transcription. A coil-coil region (residues 135–320) affords an extensive surface that could serve to interact with other nuclear proteins and is known to do so in several cases (912). Finally, a C-terminal 38-amino acid segment binds the coactivator p300/CBP and is required for IFN-{gamma}-induced transcriptional activation (1316).

Despite this progress, many detailed mechanistic questions about STAT function remain, particularly because STAT molecules will likely participate in cooperative transcription factor clusters called enhanceosomes (4, 11, 17). In particular, it is unknown whether STATs contain transcriptional activation domains other than the C-terminal domain that interacts with p300 and whether cognate-interacting factors function (like p300) in chromatin remodeling or at subsequent steps. The analysis of STAT function through in vitro transcription should both illuminate details of STAT function in transcriptional activation and provide the opportunity to study biochemical details of enhanceosome function for individual genes. Accordingly, we have explored in vitro transcription with STAT1 and mutant STAT1 proteins on both naked DNA and corresponding reconstituted chromatin templates. These latter results have been correlated with in vivo chromatin immunoprecipitation assays, and the combined results argue for distinct activation domains that function in chromatin modification and in a subsequent step(s).


    EXPERIMENTAL PROCEDURES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Recombinant Proteins—N-terminal His6-tagged STAT1{alpha}, STAT1{beta}, and all STAT1 mutants were produced in Sf9 cells by means of baculovirus vectors and purified by standard techniques (Bac-to-Bac baculovirus expression system, Invitrogen). Purified STATs were treated with T4 endonuclease V-protease to remove His6 tags. All STAT proteins were modified by phosphorylation on Tyr-701 by in vitro activated epidermal growth factor receptor as described (6). His6-tagged NAP-1 was expressed in Escherichia coli and purified by Ni2+ agarose batch binding and elution followed by MonoQ column chromatography (18). FLAG-tagged ISWI and Acf1 were co-expressed via baculovirus vectors in Sf9 cells and co-purified as a complex (ACF) by anti-FLAG affinity batch binding and elution as described previously (19). His6-tagged p300 and CBP were expressed and purified from baculovirus-infected Sf9 cells.

DNA Templates—Transcription reactions with STATs were carried out with the test plasmid pLy6E/G-less, which contained three STAT-binding sites from the mouse LY6E gene (20). These three IFN-{gamma}-activated sites were placed upstream of the adenovirus major late core promoter (21) followed by a G-less cassette; the construct is referred to as pLy6ML{Delta}53 or as pLy6. The control plasmid, pML{Delta}53, lacked activator binding sites and contained the adenovirus major late promoter followed by a G-less cassette shorter than that in the LY6E plasmid. The plasmid pA4xML{Delta}53 (22) contains four cognate sites for HNF-4 upstream of the same core promoter.

Chromatin Assembly—The assembly of chromatin with purified recombinant ACF, purified recombinant dNAP1, purified core histones from chicken erythrocytes (Upstate Biotechnology), pLy6E/G-less plasmid DNA, and ATP was performed as described (19). The assembly of chromatin with the Drosophila S190 extract was carried out as described (23). The resulting chromatin samples were subjected to micrococcal nuclease digestion analysis to confirm the appropriate distribution of periodic arrays.

In Vitro Transcription—In vitro transcription reactions other than those seen in Fig. 3 were performed with HeLa nuclear extract (24). For reactions with naked DNA, STAT1 proteins were incubated with pLy6E/G-less for 20 min at 30 °C. After the addition of HeLa nuclear extract, reactions were incubated at 30 °C for 20 min before adding nucleoside triphosphates. RNA synthesis was allowed to proceed for 45–60 min at 30 °C. With chromatin templates, STAT1, p300/CBP, acetyl-CoA (Sigma), and HeLa nuclear extract were added as indicated subsequent to the completion of chromatin assembly (Fig. 1). After pre-initiation complex formation (30 min at 30 °C), NTPs were added and transcription was allowed to proceed for 60 min at 30 °C. Measurement of the transcription product was carried out as described (25). In vitro transcription reactions in Fig. 3 were performed with purified factors as described (26, 27). Reactions contained 10 ng of TFIIA, 10 ng of TFIIB, ~50 ng of TFIID (containing 5 ng equivalent of TATA box-binding protein), 5 ng of TFIIE{alpha}, 2.5 ng of TFIIF{beta}, 25 ng of TFIIF, 20 ng of TFIIH, and 50 ng of Pol II. As indicated, reactions were supplemented with 1.5 µg of the USA preparation (see Fig. 3A) or 150 ng of positive cofactor 4 and ~50–100 ng of TRAP/Mediator purified from extracts of a cell line expressing a tagged mediator component (27) (see Fig. 3, B and C).



View larger version (27K):
[in this window]
[in a new window]
 
FIG. 3.
STAT1{alpha}- and STAT1{beta}-dependent transcriptional activation on naked DNA in a purified transcription system. A, USA-dependent transcriptional activation by phosphorylated forms of STAT1{alpha} and STAT1{beta}. B and C, TRAP/Mediator-dependent transcriptional activation. As indicated, reactions contained phosphorylated or unphosphorylated forms of STAT1 proteins (25 ng except in panel B, lanes 4 and 8, where 50 ng of each were used), HNF-4 (50 ng), USA (1.5 µg), purified TRAP/Mediator (~50–100 ng), and general transcription factors as indicated under "Experimental Procedures."

 


View larger version (31K):
[in this window]
[in a new window]
 
FIG. 1.
Protocols for in vitro transcription reaction on naked DNA (A) and chromatin templates (B). Templates are described in each figure. NTPs, nucleoside triphosphatases; NE, nuclear extract; PIC, pre-initiation complex; AcCoA, acetylcoenzyme A. Micrococcal nuclease digests of chromatins assembled with Drosophila S190 extract (C) and recombinant proteins (D).

 

Cell Culture—U3A (lacking STAT1), U3A-G8 (containing STAT1{alpha}), and U3A-B20 (containing STAT1{beta}) cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. HeLa cells were grown in Joklik medium supplemented with 10% fetal bovine serum. All media were supplemented with 100 µg/ml penicillin-streptomycin mix (Invitrogen). Cells were grown at 37 °C under 5% CO2. Cells bred were treated with IFN-{gamma} (1000 units/ml) for chromatin immunoprecipitation (ChIP) experiments.

Electrophoretic Mobility-shift Assay—A DNA probe of 155 base pairs (–210 to –55) containing three STAT1 binding sites was obtained by PCR with the pLy6E/G-less cassette. Unless indicated otherwise, 100 ng of recombinant tyrosine-phosphorylated STAT1 was incubated with 1 ng of 32P-labeled DNA probe for 20 min at room temperature. The protein-DNA complexes were analyzed as described previously (28, 29).

ChIP Assay—One 15-cm dish of U3A cells was treated with INF-{gamma} for the specified time, formaldehyde was added to the culture medium to a final concentration of 1%, and treated cells were incubated for 10 min at room temperature to cross-link the protein-DNA complexes. Cells were washed and collected in ice cold phosphate-buffered saline with 1 mM phenylmethylsulfonyl fluoride, 1 µg/ml aprotinin, and 1 µg/ml pepstatin A. After centrifugation at 4 °C (1200 rpm), cell pellets were resuspended in 1 ml of SDS lysis buffer (1% SDS, 10 mM EDTA, and 50 mM Tris-HCl, pH 8) and rotated at 4 °C for 10 min. The cell lysate was then sonicated to reduce the DNA length to 200–500 base pairs. Debris was removed by centrifugation (13,000 rpm) for 10 min at 4 °C. Supernatant was collected and diluted 10-fold in IP buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH 8, 167 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, 1 µg/ml aprotinin, and 1 µg/ml pepstatin A). One percent of the chromatin solution was kept to check the amount of input DNA present in different samples. 1 µg of appropriate antibody was added to the remaining chromatin solution and incubated overnight at 4 °C with rotation. 60 µl of 50% protein A agarose slurry containing 20 µg of sonicated salmon sperm DNA and 1 mg/ml bovine serum albumin (Upstate Biotechnology) were added to immune complexes and incubated for 1 h at 4 °C. Beads were collected by centrifugation and washed once with buffer I (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8, 150 mM NaCl) and twice with Tris-EDTA, pH 8. Immune complexes were eluted by incubating pelleted beads with 500 µl of 1% SDS in 0.1 M NaHCO3 for 30 min at room temperature with rotation. The supernatant fraction was collected by centrifugation. 20 µlof5 M NaCl was then added, and crosslinks were reversed by heating the eluates at 65 °C for 4 h. 10 µl of 0.5 M EDTA, 20 µl of 1 M Tris-HCl, pH 6.8, and 2 µl of 10 mg/ml proteinase K were added to the eluates, and samples were incubated for 1 h at 45 °C. DNA was recovered by phenol/chloroform extraction and ethanol precipitation using 20 µg of glycogen as a carrier. DNA samples were then analyzed with 28 cycles of PCR to amplify IRF-1 promoter sequences. The nucleotide sequences of the primers used for the PCR reaction were 5'-CTTCGCCGCTAGCTCTAC-3' and 5'-GCTCCGGGTGGCCTCGG.

RT-PCR—Total RNA was isolated from U3A cells using TRIzol reagent (Invitrogen). The PCR conditions to detect IRF-1 mRNA were as follows: 94 °C, 30 s; 50 °C, 1 min; 72 °C, 30 s; and repeat 22 cycles. Primers used were as described (30).

DNase I Primer Extension Footprinting on Chromatin—600 ng of an ACF-assembled chromatin template was incubated with or without 150 ng of phospho-STAT1 followed by DNase I digestion and primer extension reaction as described previously (31). The 5'-end of the primer used for the extension reaction corresponds to the –210 position of the template. The three STAT binding sites are located at the –110, –130, and –155 positions.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
In Vitro Function of STATs on DNA versus Chromatin Templates—STATs must be phosphorylated on tyrosine (residue 701 in STAT1) to dimerize and bind DNA (21, 32). In addition, maximal in vivo transcriptional activity requires phosphorylation of a C-terminal serine residue (Ser-727 in STAT1) (33). Purified, tyrosine-phosphorylated full-length STAT1 can be most efficiently prepared in large quantities by production in baculovirus-infected insect cells and subsequent tyrosine phosphorylation by activated epidermal growth factor receptor (6). STAT1 prepared in this fashion is completely and exclusively phosphorylated on Tyr-701, with no evidence of Ser-727 phosphorylation (estimated limit of detection is ~5%) from mass spectrometric analysis (data not shown). Because transcription is only reduced and not ablated in cells when Ser-727 is changed to alanine (33), we performed in vitro transcriptional experiments with the purified, tyrosine phosphorylated STAT1 without attempting to phosphorylate Ser-727.

The test DNA template contained three STAT1 binding sites upstream of the adenovirus major late core promoter (20, 21) followed by a G-less cassette, whereas a control template contained only the adenovirus core promoter (–53 to +10) and a shorter G-less cassette. The STAT1 binding sites on the plasmid (pLy6) were from the IFN-{gamma}-induced murine Ly6E gene and were shown previously to function on model templates in vivo (21).

Two transcription systems were employed to analyze the coactivator-dependence of the transcriptional activity of STAT proteins. One system (26) consisted of the following: highly purified RNA polymerase II from HeLa cells; affinity purified preparations of recombinant general transcription factors TFIIA, TFIIB, TFIIE, and TFIIF; an enriched chromatographic fraction from HeLa cell nuclear extract containing TFIIH; and TFIID that was affinity-purified from HeLa cells expressing epitope-tagged TATA box-binding protein. Consistent with earlier results (26, 34, 35), this system supports basal (activator-independent) transcription from templates (including pLy6, see below) that contain the adenovirus major late promoter. However, to support activator-dependant transcription, this system requires additional cofactors, such as those present in the previously described USA fraction (34, 36). A major activity in the USA fraction was recently identified as a Mediator-like complex (27), the key transcriptional coactivator in eukaryotic cells (3739). Therefore, to identify a potential role for the Mediator in STAT1-dependent transcriptional activation, the system that supports basal transcription was supplemented with affinity-purified USA or TRAP/Mediator fractions.

A second transcription system used to compare STAT and coactivator-dependent transcription from DNA and chromatin templates employed HeLa cell nuclear extract as a source of all necessary components of the transcriptional machinery. The protocols and the order of addition of reagents are shown in Fig. 1A (DNA) and Fig. 1B (Chromatin). Chromatin templates for all experiments except those seen in Fig. 5 were prepared according to Ito et al. (18), and samples of chromatin preparations digested with micrococcal nuclease are shown in Fig. 1, C and D.



View larger version (36K):
[in this window]
[in a new window]
 
FIG. 5.
Transcriptional effects of phosphorylated wild-type versus mutant (S247A and S727A) STAT1 proteins. Comparison of DNA binding by electrophoretic mobility-shift assay (A) and transcriptional stimulation on naked DNA (B) and chromatin (C) templates. Reactions in A and B contained increasing amounts (5, 15, and 50 ng) of the indicated STAT1 proteins. Templates were naked DNA, as in Fig. 2B. Reactions in C contained 50 ng of the indicated STAT1 proteins and 50 ng of CBP as indicated (C), and templates were as in Fig. 2C. Transcription was assayed with HeLa nuclear extract according to the protocol of Fig. 1A.

 



View larger version (39K):
[in this window]
[in a new window]
 
FIG. 2.
DNA binding ability of STAT1{alpha} and STAT1{beta} was determined by electrophoretic mobility-shift assay (A) and in vitro transcriptional stimulation by STAT1{alpha} and STAT1{beta} on naked DNA (B) and chromatin (C) templates. Reactions in A and B contained increasing amounts (5–100 ng) of the indicated STAT1 proteins, whereas reactions in C contained, as indicated, 50 ng of STAT1{alpha} or STAT1{beta} and 100 ng of p300. The plasmid DNAs contained STAT binding sites (pLy6) or no STAT sites ({Delta}53, see "Experimental Procedures"). In Fig. 2A, the fastest migrating band is a dimer of STAT1{alpha} or -{beta}, and the slower band is a dimer-dimer complex. Transcription was carried out with HeLa nuclear extract (50 µg) in the absence of acetyl-CoA according to the protocols of Fig. 1A.

 
STAT1{alpha} is the wild-type full-length transcriptional activator, and STAT1{beta} is a naturally occurring splice variant (40) that lacks the C-terminal transcriptional activation domain which can bind the histone acetyltransferases p300/CBP (14, 15). Both STAT1{alpha} and STAT1{beta} bind DNA, with STAT1{alpha} showing a stronger tendency to form dimer-dimer complexes (Ref. 6 and Fig. 2A). In crude nuclear extracts containing the general transcription machinery and various cofactors, tyrosine-phosphorylated STAT1{alpha} and STAT1{beta} both stimulated transcription (above the basal level) from the test DNA template (pLy6) but not from the control (pML{Delta}53) template (Fig. 2B).

Using the partially purified transcription system that depends upon the USA coactivator fraction, we tested the ability of STAT1{alpha} and STAT1{beta} to activate naked DNA templates (Fig. 3A). Under the conditions of the assay, basal level transcription on naked DNA was seen both from the test (pLy6) plasmid containing STAT binding sites and the reference template lacking these sites (pA4xML{Delta}53) (Fig. 3A, lane 1). Consistent with the necessity of tyrosine phosphorylation of STAT1 for dimerization and DNA binding, neither unphosphorylated STAT1{alpha} (Fig. 3A, lane 2) nor unphosphorylated STAT1{beta} (Fig. 3A, lane 3) displayed any activity. By contrast, both phosphorylated forms of STAT1 significantly stimulated transcription from the test template (Fig. 3A; compare lanes 4 and 5 with lanes 2 and 3, respectively) in the presence of added USA. As a positive control, the transcriptional activator HNF-4 increased transcription from the reference template, which contained HNF-4 binding sites (Fig. 3A, lane 6) (22).

In a further analysis, the reconstituted transcription system containing pure preparations of all required factors (26) was used to test directly the TRAP/Mediator-dependence of STAT/function (Fig. 3, B and C). In the absence of added TRAP/Mediator there was no transcriptional activation either by phosphorylated STAT1{alpha} (Fig. 3A, lanes 3 and 4) or by HNF-4 (Fig. 3A, lane 2; used as a positive control). However, when this reconstituted system was supplemented with affinity-purified TRAP/Mediator, activation by both STAT1{alpha} (Fig. 3A, lanes 7 and 8 versus lane 5) and HNF-4 (Fig. 3A, lane 6 versus lane 5) was evident. Separately, we further found that phosphorylated STAT1{beta} was also able to activate transcription of the naked DNA template with the aid of the TRAP/Mediator complex (Fig. 3C). Overall, these results strongly implicate TRAP/Mediator in the function of STAT1 on naked DNA templates in vitro, and this stimulation can occur (perhaps less well; Fig. 3A, lanes 4 and 5) without the c-terminal STAT1 transactivation domain.

We next examined the ability of STAT1 to activate transcription on chromatin templates (pLy6 and p{Delta}53ML). The low level basal transcription observed with the naked DNA templates was completely repressed on chromatin templates (Fig. 2C, lanes 1 and 2, and Fig. 4, lane 1). Significantly, transcriptional activation was observed with STAT1{alpha} but not with STAT1{beta} (Fig. 2C, lanes 3 and 5 versus lane 1). Furthermore, preincubation with p300 (Fig. 2C, lanes 3–6) or CBP (data not shown) prior to adding the transcribing extract stimulated chromatin transcription by STAT1{alpha} but not STAT1{beta}. In addition to the stimulation by added p300 (a histone acetyltransferase), further stimulation was achieved upon the addition of acetyl-CoA as an acetyl donor (Fig. 4, lane 3 versus lane 2). These results are in accord with the conclusion of in vivo experiments that at least one function of the carboxyl-terminal STAT1 domain is binding CBP/p300 (11). By analogy with the function of this coactivator in mediating other transcriptional events (Ref. 41 and references therein), these results suggest that transcriptional activation by STAT1 involves p300-mediated acetylation of histones to promote access of the transcriptional machinery.



View larger version (41K):
[in this window]
[in a new window]
 
FIG. 4.
p300-dependent and acetyl-CoA-stimulated transcriptional activation by STAT1{alpha} on an ACF-assembled chromatin template. Reactions contained 400 ng of chromatin, 100 ng of p300, and 50 ng of phosphorylated STAT1{alpha} as indicated. Transcription was assayed with HeLa nuclear extract (50 µg) according to the protocol of Fig. 1. (p{Delta}53 plasmid DNA was added after chromatin formation to serve as a positive transcription control.)

 

To compare possible in vitro contributions of the STAT1{alpha} C terminus with known in vivo functions, transcriptional stimulation by the wild-type protein was compared with stimulation by two mutant proteins in vitro. First, Ser-727, the known phosphorylation site required for full IFN{gamma}-induced transcriptional activity of STAT1, was changed to alanine (S727A). A second mutant (L724A) contained a leucine to alanine change at residue 724. Both of these mutations reduce IFN{gamma}-induced transcriptional activity ~3-fold when expressed in cells lacking STAT1 (16). The L724A and S727A proteins bound DNA similarly to wild-type STAT1 (Fig. 5A) and, when assayed on a naked DNA template in a nuclear extract, both the L724A and the S727A proteins increased transcription to approximately the same extent as wild-type protein (Fig. 5B).

On similarly assayed chromatin templates, the two STAT1{alpha} mutants showed no transcriptional activity (Fig. 5C). However, addition of ectopic CBP to the nuclear extract resulted in significant stimulation of transcription by the mutant proteins, as well as stimulation by wild-type protein. These results agree with the known role of the C terminus in binding CBP/p300 and suggest a decreased affinity of CBP/p300 for the L724A and S727A mutant proteins, as was suggested but not demonstrated earlier (16). The relative activities of the mutant and wild-type proteins in vitro approximate the levels observed in transfection assays in vivo (16).

Binding of STATs to Specific Sites within Chromatin—Because STAT1{beta} did not stimulate transcription on a chromatin template, we employed DNaseI footprint analysis to determine whether it could bind to its cognate sites in chromatin. After incubation with STAT1{alpha} or STAT1{beta}, chromatin templates were treated with DNaseI, and the resulting DNA fragments were purified and analyzed by radiolabeled primer extension and resolved on acrylamide gels. STAT1{alpha} and {beta} gave similar footprints on the chromatin template, with all three STAT1 binding sites (indicated by lines) protected at the protein:DNA ratio used in this experiment (Fig. 6). Thus, the failure of STAT1{beta} to stimulate transcription on chromatin templates was not caused by a failure to bind to cognate sites.



View larger version (33K):
[in this window]
[in a new window]
 
FIG. 6.
Demonstration of STAT1{alpha} and STAT1{beta} binding to ACF-assembled chromatin templates by DNaseI footprint analysis. The STAT1 binding sites are indicated by vertical lines.

 

IFN-{gamma}-induced Association of STATs and p300 with the Promoter of a Chromosomal IFN-{gamma}-responsive Gene—We next tested whether STAT1{alpha} and -{beta} could bind to natural chromosomal loci in vivo. U3 cells, which lack STAT1 (13), were stably transfected with either STAT1{alpha} or STAT1{beta} (Fig. 7). STAT1{alpha}, but not STAT1{beta}, restored the IFN-{gamma}-induced response of the endogenous IRF-1 gene (Fig. 7A). To test for association of STAT1{alpha} or STAT1{beta} with the endogenous IRF-1 promoter, STAT1{alpha}- or STAT1{beta}-expressing cells were treated with IFN-{gamma}, and samples were taken at intervals for ChIP (after crosslinking and sonication) with an antibody that recognizes a common epitope in STAT1{alpha} and STAT1{beta}. There was an interferon-dependent increase of IRF-1 promoter DNA in the chromatin immunoprecipitates of extracts from both STAT1{alpha}- and STAT1{beta}-expressing cell lines (Fig. 7B), showing that both proteins (1{alpha} and 1{beta}) bind to natural sites within chromatin in vivo. Next, chromatin immunoprecipitation using p300 antibody was carried out to see whether both STAT1{alpha} and STAT1{beta} would lead to accumulation of p300 on STAT sites within chromatin. Significantly, and despite equal binding of STAT1{alpha} and STAT1{beta} to chromatin sites (Fig. 7B), only STAT1{alpha} recruited p300 to these sites (Fig. 7C). As a control in the chromatin immunoprecipitation experiments, an upstream region 3 kb from the start site was tested and not found to be precipitated by either STAT or p300 antibodies (data not shown).



View larger version (31K):
[in this window]
[in a new window]
 
FIG. 7.
A, IFN-{gamma}-induced IRF-1 mRNA in U3 cell lines expressing STAT1{alpha} or STAT1{beta}. Cytoplasmic RNAs from IFN-{gamma}-induced (+)(4 h) or -uninduced (–) U3 cells and U3 cells stably transfected with an expression plasmid for STAT1{alpha} (G8) or STAT1{beta} (B20) were analyzed for IRF-1 mRNA by RT-PCR (GAPDH used as a control mRNA). Western blots showed approximately equal STAT1{alpha} and STAT1{beta} in G8 and B20 cell lines, respectively. B, STAT1{alpha} and STAT1{beta} binding to the chromosomal IRF-1 gene after induction by IFN-{gamma}. Occupancy of the IRF-1 gene promoter in U3 cells and in cells derived there from expressing STAT1{alpha} (G8) or STAT1{beta} (B20) was analyzed by chromatin immunoprecipitation with an antibody specific for an epitope common to STAT1{alpha} and STAT1{beta}. Cells were analyzed after incubation for 4 h in the absence (–) or presence (+) of IFN-{gamma}. C, p300 binding to the chromosomal IRF-1 gene after induction by IFN-{gamma}. Occupancy of the IRF-1 promoter in U3 cell lines stably transfected with an expression plasmid for STAT1{alpha} (G8) or STAT1{beta} (B20) was analyzed by chromatin immunoprecipitation with anti-p300 polyclonal antibody (Santa Cruz Biotechnology, Inc.). Cells were treated with IFN-{gamma} for the indicated times.

 


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The in vitro experiments described in this paper establish that STAT1 molecules bound to known DNA recognition sites for STAT1 can effect recruitment of the transcriptional machinery and stimulate transcriptional initiation on both naked DNA and chromatin templates. The demonstrated ability of STAT1{alpha}, but not STAT1{beta}, to stimulate in vitro transcription of a chromatin template is in accord with earlier mutagenesis, protein-protein association and transfection experiments that demonstrated a stimulatory role of the STAT1{alpha}-specific carboxyl terminus in STAT-induced transcription (16, 33). However, the observation that STAT1{beta}, as well as STAT1{alpha}, stimulates transcription of naked DNA revealed a heretofore unrecognized transcriptional activation function common to STAT1{alpha} and STAT1{beta} and further suggested that STAT1 ({alpha} and {beta}) could also interact with proteins other than those (such as p300/CBP) involved in chromatin remodeling. Using a partially purified transcription system, we have shown that one such factor involved in STAT-dependent transcriptional activation is the TRAP/Mediator complex. Given that several transcription activators have been shown to act in part through direct interactions with TRAP/Mediator (37), we have made extensive, but thus far unsuccessful, efforts to show physical interactions of STAT1 (either free or DNA-bound and with or without phosphorylation) with the TRAP/Mediator complex. Thus, there may be other intermediary proteins linking STAT1 with TRAP/Mediator or, alternatively, the putative direct association may be weak and dependent upon cooperative interactions that are manifested only in the presence of the general transcription machinery (42). In this regard, STAT1 contains a relatively weak activation domain by comparison to other activators or to STAT2 (43). Moreover, the recent demonstration (44) of physical and functional interactions of STAT2 with the TRAP170/vitamin D receptor-interacting protein 150 component of Mediator establishes the concept, suggested here only from functional studies, of STAT-Mediator interactions. In addition, as indicated above, the ability of both STAT1{alpha} and STAT1{beta} to mediate transcription from DNA templates suggests a secondary activation domain distinct from the C-terminal domain that has been linked thus far only to p300/CBP recruitment.

Recent studies have shown that activator- and p300-dependent transcription from chromatin templates depends upon promoter-localized acetylation of nucleosomal histones (Ref. 41 and references therein). Hence, the present demonstration of in vitro transcriptional enhancement on chromatin templates by p300/CBP and acetyl-CoA makes it likely that histone acetylation is required at or near the promoter for maximal STAT1-driven transcription. The ability of STAT1{alpha}, but not STAT1{beta}, to activate transcription from a chromatin template in the presence of p300 and acetyl-CoA further suggests (see also below) that STAT1{alpha}, presumably through the C-terminal 38 amino acids, can recruit CBP/p300 whereas STAT1{beta} cannot. Thus, if there is a role for the reported p300/CBP binding site in the N terminus of STAT1{alpha} and STAT1{beta} (15), it is insufficient for significant independent action. It is also possible that other chromatin remodeling proteins and histone transacetylase may be involved in STAT1-mediated gene activation. For example, STAT2 is known to interact with GCN5 (45). However, the ~200 amino acid carboxyl terminus of STAT2 is very different from that of STAT1.

In strong support of the conclusions of the in vitro transcription studies, in vivo chromatin immunoprecipitation analyses showed that whereas both STAT1{alpha} and STAT1{beta} can accumulate on the IFN{gamma}-induced IRF-1 promoter in vivo, only STAT1{alpha} is capable of recruiting CBP/p300 and stimulating transcription. This establishes the primary importance of the earlier demonstrated C-terminal STAT1-CBP/p300 interaction relative to the N-terminal STAT1-CBP/p300 interaction (16) and, most importantly, elucidates the specific step at which this C-terminal activation domain functions.

The in vitro system faithfully reproduces the decreased ability of STAT1 mutants to stimulate transcription in vivo (16). Thus, STAT1 L724A and S727A are poor activators on chromatin templates compared with wild-type protein, although they do show some activity. The basis for stronger activation by the natural amino acid sequence in the activation domain may include a more avid binding of p300/CBP due to Ser-727 phosphorylation or the presence of the Leu-724 residue. However, the ability of an increased level of CBP to stimulate transcription by both mutants suggests that they bind this co-activator less well than wild-type protein.

The present study of STAT1 function on DNA versus chromatin templates has allowed the resolution of distinct activation domains and corresponding functions with distinct coactivators acting at chromatin remodeling versus post-chromatin remodeling steps. They also open the way for further identification of other factors that may be recruited by activated STAT1 molecules in the course of IFN-{gamma}-stimulated gene transcription. Because all of the STAT proteins are so similar (particularly STAT3, which is 45% identical in amino acid sequence to STAT1), these results also suggest likely success in studies of other STAT molecules where in vivo interactions with other transcription factors have been documented (11, 12, 46).


    FOOTNOTES
 
* This work was supported by National Institutes of Health Grants AI34420 and AI32489 (to J. E. D.) and CA42567 (to R. G. R.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

§ These authors contributed equally to this work. Back

** To whom correspondence should be addressed. Tel.: 212-327-8791; Fax: 212-327-8801; E-mail: darnell{at}mail.rockefeller.edu.

1 The abbreviations used are: STAT, signal transducers and activators of transcription; IFN, interferon; CBP, cAMP-response element-binding protein; HNF, hepatocyte nuclear factor; TF, transcription factor; USA, upstream activator; TRAP, thyroid hormone receptor-associated proteins; ChIP, chromatin immunoprecipitation; IRF-1, IFN regulatory factor-1. Back


    ACKNOWLEDGMENTS
 
We thank Dr. Dmitry V. Fyodorov for assistance with chromatin assembly assay. We also thank the following for providing valuable reagents: Jim Kadonaga for ACF1 and p300, Carl Wu for ISWI, and Tsutomu Ohta for Nap1.



    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Darnell, J. E., Jr., Kerr, I. M., and Stark, G. M. (1994) Science 264, 1415–1421[Abstract/Free Full Text]
  2. Stark, G. R., Kerr, I. M., Williams, B. R., Silverman, R. H., and Schreiber, R. D. (1998) Annu. Rev. Biochem. 67, 227–264[CrossRef][Medline] [Order article via Infotrieve]
  3. Levy, D., and Darnell, J. E., Jr. (2002) Nat. Rev. Mol. Cell Biol. 3, 651–662[CrossRef][Medline] [Order article via Infotrieve]
  4. Horvath, C. M. (2000) Trends Biochem. Sci. 25, 496–502[CrossRef][Medline] [Order article via Infotrieve]
  5. Chen, X., Vinkemeier, U., Zhao, Y., Jeruzalmi, D., Darnell, J. E., Jr., and Kuriyan, J. (1998) Cell 93, 827–839[CrossRef][Medline] [Order article via Infotrieve]
  6. Vinkemeier, U., Cohen, S. L., Moarefi, I., Chait, B. T., Kuriyan, J., and Darnell, J. E., Jr. (1996) EMBO J. 15, 5616–5626[Medline] [Order article via Infotrieve]
  7. Vinkemeier, U., Moarefi, I., Darnell, J. E., Jr., and Kuriyan, J. (1998) Science 279, 1048–1052[Abstract/Free Full Text]
  8. Xu, X., Ya-Lin, S., and Hoey, T. (1996) Science 273, 794–797[Abstract]
  9. Horvath, C. M., Stark, G. R., Kerr, I. M., and Darnell, J. E., Jr. (1996) Mol. Cell. Biol. 16, 6957–6964[Abstract]
  10. Stoecklin, E., Wissler, M., Gouilleux, F., and Groner, B. (1996) Nature 383, 726–728[CrossRef][Medline] [Order article via Infotrieve]
  11. Zhang, X., Wrzeszczynaska, M. H., Horvath, C. M., and Darnell, J. E., Jr. (1999) Mol. Cell. Biol. 19, 7138–7146[Abstract/Free Full Text]
  12. Look, D. C., Pelletier, M. R., Tidwell, R. M., Roswit, W. T., and Holtzman, M. J. (1995) J. Biol. Chem. 270, 30264–30267[Abstract/Free Full Text]
  13. Muller, M., Laxton, C., Briscoe, J., Schindler, C., Improta, T., Darnell, J. E., Jr., Stark, G. R., and Kerr, I. M. (1993) EMBO J. 12, 4221–4228[Medline] [Order article via Infotrieve]
  14. Horvai, A. E., Xu, L., Korzus, E., Brard, G., Kalafus, D., Mullen, T.-M., Rose, D. W., Rosenfield, M. G., and Glass, C. K. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 1074–1079[Abstract/Free Full Text]
  15. Zhang, J. J., Vinkemeier, U., Gu, W., Chakravarti, D., Horvath, C. M., and Darnell, J. E., Jr. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 15092–15096[Abstract/Free Full Text]
  16. Zhang, J. J., Zhao, Y., Chait, B. T., Lathem, W. W., Ritzi, M., Knippers, R., and Darnell, J. E., Jr. (1998) EMBO J. 17, 6963–6971[CrossRef][Medline] [Order article via Infotrieve]
  17. Carey, M. (1998) Cell 92, 5–8[CrossRef][Medline] [Order article via Infotrieve]
  18. Ito, T., Ikehara, T., Nakagawa, T., Kraus, W. L., and Muramatsu, M. (2000) Genes Dev. 14, 1899–1907[Abstract/Free Full Text]
  19. Ito, T., Evenstein, M. E. L., Fyodorov, D. V., Kutach, A. K., Kobayashi, R., and Kadonaga, J. T. (1999) Genes Dev. 13, 1529–1539[Abstract/Free Full Text]
  20. Khan, K. D., Shuai, K., Lindwall, G., Maher, S. E., Darnell, J. E., Jr., and Bothwell, A. L. M. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 6806–6810[Abstract/Free Full Text]
  21. Shuai, K., Stark, G. R., Kerr, I. M., and Darnell, J. E., Jr. (1993) Science 261, 1744–1746[Abstract/Free Full Text]
  22. Malik, S., and Karathanasis, S. K. (1996) Mol. Cell. Biol. 16, 1824–1931[Abstract]
  23. Bulger, M., and Kadonaga, J. T. (1994) Methods Mol. Genet. 5, 241–262
  24. Dignam, J. D., Lebovitz, R. M., and Roeder, R. G. (1983) Nucleic Acids Res. 11, 1475–1489[Abstract/Free Full Text]
  25. Pognonec, P., and Roeder, R. G. (1991) Mol. Cell. Biol. 11, 5125–5136[Abstract/Free Full Text]
  26. Malik, S., Guermah, M., and Roeder, R. G. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 2192–2197[Abstract/Free Full Text]
  27. Malik, S., Gu, W., Wu, W., Qin, J., and Roeder, R. G. (2000) Mol. Cell 5, 753–760[CrossRef][Medline] [Order article via Infotrieve]
  28. Fried, M., and Crothers, D. M. (1981) Nucleic Acids Res. 9, 6505–6525[Abstract/Free Full Text]
  29. Yang, E., Henriksen, M. A., Schaefer, O., Zakharova, N., and Darnell, J. E., Jr. (2002) J. Biol. Chem. 277, 13455–13462[Abstract/Free Full Text]
  30. Yang, E., Wen, Z., Haspel, R. L., Zhang, J. J., and Darnell, J. E., Jr. (1999) Mol. Cell. Biol. 19, 5106–5112[Abstract/Free Full Text]
  31. Fyodorov, D. V., and Kadonaga, J. T. (2002) Nature 418, 897–900[Medline] [Order article via Infotrieve]
  32. Shuai, K., Horvath, C. M., Tsai-Huang, L. H., Qureshi, S., Cowburn, D., and Darnell, J. E., Jr. (1994) Cell 76, 821–828[CrossRef][Medline] [Order article via Infotrieve]
  33. Wen, Z., Zhong, Z., and Darnell, J. E., Jr. (1995) Cell 82, 241–250[CrossRef][Medline] [Order article via Infotrieve]
  34. Meisterernst, M., Roy, A. L., Lieu, J. M., and Roeder, R. G. (1991) Cell 66, 981–993[CrossRef][Medline] [Order article via Infotrieve]
  35. Ge, H., Martinez, E., Chiang, C. M., and Roeder, R. G. (1996) Methods Enzymol. 274, 57–71[Medline] [Order article via Infotrieve]
  36. Kaiser, K., and Meisterernst, M. (1996) Trends Biochem. Sci. 21, 342–345[CrossRef][Medline] [Order article via Infotrieve]
  37. Malik, S., and Roeder, R. G. (2000) Trends Biochem. Sci. 25, 277–283[CrossRef][Medline] [Order article via Infotrieve]
  38. Lee, T. I., and Young, R. A. (2000) Annu. Rev. Genet. 34, 77–137[CrossRef][Medline] [Order article via Infotrieve]
  39. Myers, L. C., and Kornberg, R. D. (2000) Annu. Rev. Biochem. 69, 729–749[CrossRef][Medline] [Order article via Infotrieve]
  40. Schindler, C., Fu, X.-Y., Improta, T., Aebersold, R., and Darnell, J. E., Jr. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 7836–7839[Abstract/Free Full Text]
  41. An, W., Palhan, V. B., Karymov, M. A., Leuba, S. H., and Roeder, R. G. (2002) Mol. Cell 9, 811–821[CrossRef][Medline] [Order article via Infotrieve]
  42. Roeder, R. G. (1998) Cold Spring Harbor Symp. Quant. Biol. 63, 201–218[CrossRef][Medline] [Order article via Infotrieve]
  43. Shen, Y., and Darnell, J. E., Jr. (2001) J. Virol. 75, 2627–2633[Abstract/Free Full Text]
  44. Lau, J. F., Nusinzon, I., Barkov, D., Freedman, L. P., and Horvath, C. M. (2003) Mol. Cell. Biol. 23, 620–628[Abstract/Free Full Text]
  45. Paulson, M., Press, C., Smith, E., Tanese, N., and Levy, D. E. (2002) Nat. Cell. Bio. 4, 140–147[CrossRef][Medline] [Order article via Infotrieve]
  46. Stoecklin, E., Wissler, M., Morrigl, R., and Groner, B. (1997) Mol. Cell. Biol. 17, 6708–6716[Abstract]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
D. Watling, C. R. Carmo, I. M. Kerr, and A. P. Costa-Pereira
Multiple kinases in the interferon-{gamma} response
PNAS, April 22, 2008; 105(16): 6051 - 6056.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
R. Christova, T. Jones, P.-J. Wu, A. Bolzer, A. P. Costa-Pereira, D. Watling, I. M. Kerr, and D. Sheer
P-STAT1 mediates higher-order chromatin remodelling of the human MHC in response to IFN{gamma}
J. Cell Sci., September 15, 2007; 120(18): 3262 - 3270.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
K. Ramsauer, M. Farlik, G. Zupkovitz, C. Seiser, A. Kroger, H. Hauser, and T. Decker
Distinct modes of action applied by transcription factors STAT1 and IRF1 to initiate transcription of the IFN-{gamma}-inducible gbp2 gene
PNAS, February 20, 2007; 104(8): 2849 - 2854.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
L. Overbergh, K. Stoffels, M. Waer, A. Verstuyf, R. Bouillon, and C. Mathieu
Immune Regulation of 25-Hydroxyvitamin D-1{alpha}-Hydroxylase in Human Monocytic THP1 Cells: Mechanisms of Interferon-{gamma}-Mediated Induction
J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3566 - 3574.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
I. Lodige, A. Marg, B. Wiesner, B. Malecova, T. Oelgeschlager, and U. Vinkemeier
Nuclear Export Determines the Cytokine Sensitivity of STAT Transcription Factors
J. Biol. Chem., December 30, 2005; 280(52): 43087 - 43099.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
S. E. Hartman, P. Bertone, A. K. Nath, T. E. Royce, M. Gerstein, S. Weissman, and M. Snyder
Global changes in STAT target selection and transcription regulation upon interferon treatments
Genes & Dev., December 15, 2005; 19(24): 2953 - 2968.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
X. Hu, K.-H. Park-Min, H. H. Ho, and L. B. Ivashkiv
IFN-{gamma}-Primed Macrophages Exhibit Increased CCR2-Dependent Migration and Altered IFN-{gamma} Responses Mediated by Stat1
J. Immunol., September 15, 2005; 175(6): 3637 - 3647.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
G. Forget, D. J. Gregory, and M. Olivier
Proteasome-mediated Degradation of STAT1{alpha} following Infection of Macrophages with Leishmania donovani
J. Biol. Chem., August 26, 2005; 280(34): 30542 - 30549.
[Abstract] [Full Text] [PDF]